Anaphylaxis is a severe systemic allergic reaction, the reported incidence of which is increasing worldwide. [1] [2] [3] Reactions are clinically heterogeneous yet characterized by rapid symptom progression and risk of death: intense vasodilation and bronchoconstriction can lead to hypotension, hypothermia, tachycardia, and respiratory distress, which can result in heart and lung failure. In children the most common causative agent is food, whereas in adults drug-induced anaphylaxis accounts for the majority of cases and the majority of fatal reactions. Anaphylaxis is classically attributed to an IgE-mediated reaction driven by mast cell activation and release of histamine and tryptase. 4 Many cases of human anaphylaxis, in particular anaphylaxis to drugs, are not accompanied by increased serum tryptase or detectable antigen-specific IgE levels. [5] [6] [7] [8] Alternative IgEindependent pathways might actually underlie a significant fraction of these anaphylactic events: indeed, non-IgE reactions have been reported to account for up to 30% of cases of drug-induced anaphylaxis. 9 Furthermore, measures of histamine and mast cell tryptase in patients' sera do not reflect the severity of reactions, 7, 10 whereas serum platelet-activating factor (PAF) levels were found to directly correlate with anaphylaxis severity. 11, 12 Supporting these notions, experimental animal models have demonstrated that fatal systemic anaphylaxis after intravenous challenge proceeds through PAF release triggered by non-IgE-dependent pathways and in particular by IgG-dependent pathways. 13, 14 However, the respective contribution of IgE-and IgG-mediated pathways in human anaphylaxis remains to be determined.
Passive systemic anaphylaxis (PSA) can be induced in mice through the transfer of specific IgE or IgG antibodies before challenge with a specific antigen or through the transfer of preformed IgG immune complexes. Active systemic anaphylaxis (ASA) is elicited by immunization with an antigen before challenge with the same antigen; a polyclonal IgE and IgG antibody response is generated, and death can result from antigen challenge. In both models use of the intravenous route for allergen challenge mimics drug-induced anaphylaxis in patients. ASA does not depend on IgE antibodies, activating IgE receptors, or mast cells 15, 16 but rather requires activating IgG receptors (FcgR) and the contribution of other myeloid cells: neutrophils, basophils, or monocyte/macrophages. [17] [18] [19] PAF was identified as the dominant downstream mediator of IgG-induced anaphylaxis, and PAF alone, like histamine, can reproduce the signs and symptoms of anaphylaxis. 20, 21 Thus mouse models suggest a pathway of anaphylaxis driven by IgG-mediated activation of myeloid cells and relying on PAF release.
Allergic patients who possess detectable allergen-specific IgE also possess detectable allergen-specific IgG. These antiallergen IgG antibodies are mainly of the IgG 1 isotype, whereas antiallergen IgG 4 antibodies increase after allergen immunotherapy. [22] [23] [24] [25] Allergen-specific IgG 4 levels are considered a good correlate to successful allergen immunotherapy; however, it remains unknown whether allergen-specific IgG 1 participates in or is even responsible for non-IgE-mediated human anaphylaxis. Human subjects express a family of IgG receptors (FcgR) comprised of activating IgG receptors (hFcgRI/CD64, hFcgRIIA/CD32A, hFcgRIIC/CD32C, hFcgRIIIA/CD16A, and hFcgRIIIB/ CD16B) and a single inhibitory receptor (hFcgRIIB/CD32B), which all bind human IgG 1 and mediate most of the biological functions of IgG. 26 Although mice also express both activating and inhibitory FcgRs, murine FcgRs do not structurally or functionally mirror those of human subjects: differential antibody binding affinities and variable expression on immune cell subsets prevent extrapolation from one species to another. 26 We reported previously the induction of anaphylaxis (PSA and fatal ASA) in mice transgenic either for hFcgRI/CD64 or hFcgRIIA/CD32A on a background deficient in endogenous mFcgR. 19, 27 PSA mediated by hFcgRIIA was independent of mast cells and basophils and relied on neutrophils and monocytes/macrophages, 28 and hFcgRI-dependent ASA required neutrophils and PAF release. 27 An important caveat of these results is that they were obtained in mice expressing only 1 hFcgR in the absence of potential regulatory or cooperative effects of other hFcgRs. In a model generated by intercrossing of 5 different hFcgR-transgenic mice, incorporating activating and inhibitory hFcgRs, administration of aggregated human IgG to (hFcgRI tg hFcgRIIA tg hFcgRIIB tg hFcgRIIIA tg hFcgRIIIB tg ) mice on a mFcgR null background was sufficient to trigger anaphylaxis, although the mechanisms were not addressed. 29 However, this model reproduces aberrant expressions seen in mice carrying the individual transgenes, including extremely high expression of hFcgRIIB on mouse monocytes and granulocytes. 26 Here we present a novel mouse model in which we used highly efficient knock-in technology to insert the entire low-affinity hFcgR locus into the corresponding mouse locus on chromosome 1. This approach engendered expression of activating hFcgRIIA/ CD32A, hFcgRIIIA/CD16A, and hFcgRIIIB/CD16B and inhibitory hFcgRIIB/CD32B in mice in a manner resembling expression patterns seen in human subjects. This unprecedented model permits analyses of the role of hFcgRs and the cell types that express them in IgG-mediated anaphylaxis within a cognate context of activating and inhibitory hFcgRs.
METHODS Mice
VG1505 and VG1543 mice were designed and generated by Regeneron Pharmaceuticals (Tarrytown, NY) on a mixed 62.5% C57BL/6N and 37.5% 129S6/SvEv genetic background (Fig 1; see also the Methods section in this article's Online Repository at www.jacionline.org) and backcrossed 1 generation to C57BL/6N. Mice were bred at Institut Pasteur (Paris, France) and used for experiments at 7 to 11 weeks of age. VG1505 and VG1543 mice demonstrate normal development and breeding patterns. Experiments using mice were validated by the CETEA ethics committee number 89 (Institut Pasteur, Paris, France) under #2013-0103, and by the French Ministry of Research under agreement #00513.02.
ASA
Mice were injected intraperitoneally on day 0 with 200 mg of BSA in complete Freund adjuvant and boosted intraperitoneally on day 14 with 200 mg of BSA in incomplete Freund adjuvant. BSA-specific IgG 1 , IgG2 a/b/c , and IgE antibodies in serum were titered by using ELISA on day 21, as previously described. 19 Mice with comparable antibody titers were challenged intravenously with 500 mg of BSA 10 to 14 days after the last immunization. Central temperature was monitored by using a digital thermometer (YSI, Yellow Springs, Ohio) with a rectal probe.
PSA
Human intravenous immunoglobulin (IVIG; Gamunex; Grifols, Los Angeles, Calif) was heat aggregated (HA) by means of incubation at 25 mg/ mL in borate-buffered saline (0.17 mol/L H 3 BO 3 and 0.12 mol/L NaCl, pH 8) for 1 hour at 638C and then diluted in 0.9% NaCl for intravenous injection at 100 mL per mouse. Central temperature was monitored with a digital thermometer with a rectal probe. Control nonaggregated IVIG was similarly diluted without heating. For hFcgR expression analysis after IVIG-PSA, heparinized blood was sampled 1 hour after IVIG injection. IgE-dependent PSA was induced by means of challenge with 500 mg of TNP-BSA 16 hours after passive transfer of IgE anti-TNP (50 mg of clone C48.2). PSAwas induced also by means of PAF injection at 0.3 mg per mouse intravenously, and hypothermia was monitored immediately afterward.
In vivo blocking and depletion
Anti-FcgRIIA mAbs (clone IV.3, 60 mg per mouse) were injected twice intravenously (24 and 4 hours) before challenge. Note that, unlike in FcgRIIA tg mice, 30 IV.3 administration did not induce hypothermia or symptoms of anaphylaxis or platelet depletion. Three hundred micrograms per mouse of anti-Gr-1 (RB6-8C5), 300 mg per mouse anti-Ly-6G (NIMP-R14), 30 mg or 60 mg per mouse anti-CD200R3 (Ba103), mAbs, or corresponding rat IgG 2b isotype control mAbs were injected intravenously 24 hours before challenge. Note that the NIMP-R14 antibody clone is specific to the Ly-6G antigen (see Fig E1, A-C, in this article's Online Repository at www. jacionline.org). Three hundred microliters per mouse of PBS or clodronate liposomes was injected intravenously either 24 hours before challenge or both 24 and 48 hours before challenge. The specificity of cell depletion was evaluated in the blood, spleen, and peritoneal lavage fluid of naive VG1543 mice 24 hours after NIMP-R14 (see Fig E1, C-E). See ''Specificity and efficiency of cell depletion strategies'' in the Methods section in this article's Online Repository for more information.
The platelet-activating factor receptor (PAF-R) antagonists ABT-491 (25 mg per mouse) or CV-6209 (66 mg per mouse) in 0.9% NaCl were injected intravenously 15 or 10 minutes before challenge, respectively. The H 1 -receptor antagonists cetirizine DiHCl, pyrilamine maleate, or triprolidine HCl at 300 mg per mouse in 0.9% NaCl were injected intraperitoneally 30 minutes before challenge.
See the Methods section in this article's Online Repository for details on generation of knock-in mice, antibodies and reagents, flow cytometry, specificity and efficiency of cell depletion strategies, and statistics. To delete the mouse low-affinity Fc receptors, a large targeting vector (BACvec) 31, 32 was constructed to delete 106 kb of mouse genomic sequence encompassing the mouse Fcgr2b, Fcgr3, and Fcgr4 genes and used to target VGF1 embryonic stem (ES) cells (as described in the Methods section in this article's Online Repository, see Tables E1-E3) . 33 The low-affinity FcgR deleted allele (deletion of 1:170,956,770-171,063,353 from Chr1_H3 based on the mouse GRCh38 assembly) was given the designation VG1505 (Fig 1, A) .
RESULTS

Creation
To insert human FCGR3A and FCGR2A genes, a BACvec containing 69 kb of the corresponding human sequence flanked by long mouse homology arms was generated (see the Methods section in this article's Online Repository) and used to retarget VG1505 ES cells. 31 The subsequent allele in which the 3 mouse low-affinity Fc receptors were replaced with hFCGR3A and hFCGR2A was given the designation VG1528 (Fig 1, B) . A BACvec was constructed containing an additional 142 kb of human sequence between a human homology arm homologous to the end of the human insert in VG1528 and a mouse homology arm to insert human FCGR2B, FCGR2C, and FCGR3B genes next to the human FCGR3A and FCGR2A genes. This BACvec was used to retarget VG1528 ES cells and resulted in an allele designated VG1543 (insertion of human sequence from 1:161,500,441-161,679,348 on Chr1_q23.3 based on the human GRCh38 assembly) 31, 32 in which all 5 human low-affinity FcgR receptor genes replace the 3 mouse low-affinity FcgR genes (Fig 1, C) . The inserted human low-affinity FcgRs are in the same order as in the human genome, and the human intergenic sequences are retained intact. The bacterial artificial chromosome (BAC) sequences used encode for the human polymorphic variants hFcgRIIA(H 131 ), hFcgRIIB(I 232 ), hFcgRIIC(Stop 13 ), hFcgRIIIA(V 158 ), and hFcgRIIIB(NA2); therefore no expression of hFcgRIIC is expected in VG1543 mice.
VG1543 mice exhibit hFcgR expression patterns on immune cells comparable with those in human subjects
First, we determined that VG1505 and VG1543 mice exhibit normal immune cell composition ( see Fig E2 and (Fig 1, B) and insertion of FCGR2B, FCGR3B, and FCGR2C genes (Fig 1, C) . The total human sequence inserted in VG1543 mice ranges from 1:161,500,441 to 1:161,679,348 on human Chr1_q23.3 based on human GRCh38. Mouse genomic coordinates are in black, human genomic coordinates are in gray, the light gray block arrow indicates hygromycin selection cassettes, dark gray block arrows indicate neomycin selection cassettes, black arrowheads represent Loxp sites, open arrowheads represent Frt sites, and gray arrowheads represent Lox2372 sites. mice demonstrate slightly increased frequencies of granulocytes and monocytes in the blood and spleen and macrophages in the peritoneum compared with VG1543 (see Fig E2, A-C, in this article's Online Repository at www.jacionline.org). Furthermore, VG1505 and VG1543 mice exhibit comparable mFcεRI and mFcgRI expression (see Fig E2, D-F) .
To compare the expression pattern of hFcgRs in VG1543 mice with that of human subjects, specific antibody staining and flow cytometric analysis were performed on cells isolated either from the blood of healthy human donors or from the blood, spleen, lymph nodes, bone marrow, peritoneum, and bronchoalveolar lavage (BAL) fluid of VG1543 mice. All myeloid cells examined, including monocytes, macrophages, eosinophils, basophils, and mast cells, and among lymphocytes B and natural killer (NK) cells, but not T cells, expressed at least 1 hFcgR (Fig 2, A and B) .
We detected hFcgRIIA (CD32A) staining on neutrophils, monocytes, eosinophils, and platelets from the blood of healthy human donors (Fig 2, A) , as expected, 26 and from the blood, spleen, lymph nodes, bone marrow, peritoneum, and BAL fluid of VG1543 mice (Fig 2, B) . VG1543 peritoneal mast cells also expressed hFcgRIIA. Like human blood basophils, VG1543 blood basophils expressed variably hFcgRIIA (Fig 2, A and B) but not basophils from the spleen or bone marrow; the low level of expression of hFcgRIIA on VG1543 blood basophils is in the range of expression found on basophils from human donors (Fig 2, C) . As expected, lymphocytes, including B, T, and NK cells, did not express hFcgRIIA in human subjects and VG1543 mice (Fig 2, A and B) ; notably, we observed some background staining for hFcgRIIA on human B cells, as published previously. 28 Thus the hFcgRIIA expression pattern and level are comparable between VG1543 mice and blood from healthy human donors.
In human blood hFcgRIIB was detected at high levels on all B cells and basophils and at lower levels variably on a proportion of monocytes (2% to 38% positive, n 5 4 donors), whereas other cells were mostly negative (ie, neutrophils, eosinophils, NK cells, T cells, and platelets; Fig 2, A, and see Fig E3, A) , as expected. 34, 35 Similarly, VG1543 mice expressed high levels of hFcgRIIB on B cells from blood, spleen, lymph nodes, and peritoneum (Fig 2, B) . Furthermore, we observed variation in hFcgRIIB staining among B-cell subpopulations isolated from the bone marrow and peritoneum in VG1543 mice (see Fig E3, B and C, in this article's Online Repository at www.jacionline. org). VG1543 mice demonstrated robust hFcgRIIB expression on monocyte populations in the blood and lymphoid organs, yet no staining was observed on Ly-6C hi monocytes from the bone marrow. Only a fraction of donors we analyzed demonstrated hFcgRIIB expression on blood monocytes (see Fig E3, A, in this article's Online Repository at www.jacionline.org), which is consistent with its previously reported variable expression on CD14 lo monocytes and absence of expression on CD14 hi monocytes. 36 Thus VG1543 mice exhibit overexpression of hFcgRIIB on blood monocytes compared with that seen on human blood monocytes. Interestingly, hFcgRIIB staining was higher on Ly-6C low ''patrolling'' monocytes than on Ly-6C hi ''classical'' monocytes from VG1543 mice (see Fig E3, D) , as it is on the analogous populations in human blood, CD14 low CD16 hi ''patrolling'' monocytes, and CD14 hi '' classical'' monocytes (see Fig E3, E) . Furthermore, spleen monocytes in human subjects 36 and VG1543 mice express significant levels of hFcgRIIB, reconciling hFcgRIIB expression on monocytes in this compartment between human donors and VG1543 mice. Macrophages from the peritoneum, but not from BAL fluid, of VG1543 mice were found to be positive for hFcgRIIB (Fig 2, B) . Although human basophils express high levels of hFcgRIIB, 37 basophils from VG1543 mice were negative (Fig 2, A and B) . Overall, VG1543 mice appear to express hFcgRIIB at similar levels on B cells, at the high end of the range on monocytes, but not on basophils, compared with human subjects.
Human neutrophils, monocytes, eosinophils, NK cells, and a small proportion of basophils were labeled positive with an anti-CD16 antibody recognizing both hFcgRIIIA and hFcgRIIIB (Fig  2, A) in accordance with known hFcgRIIIA (NK cells, monocytes/ macrophages, and eosinophils) and hFcgRIIIB expression (neutrophils and some basophils). 35 Similarly, in the blood and organs from VG1543 mice, neutrophils stained at high levels and monocyte/macrophages, NK cells, and basophils stained at variable levels with anti-CD16 (Fig 2, B , and see Fig E3, D) . Eosinophils from VG1543 mice did not show detectable CD16 labeling, which is in accordance with 25% of human donors (see Fig E3,  F) . Interestingly, CD16 was apparent on only 30% to 45% of NKp46 1 NK cells from the spleens of VG1543 mice compared with 85% to 98% of CD56 1 NK cells from human blood. Overall, VG1543 mice appear to express hFcgRIIIA and hFcgRIIIB at similar levels on neutrophils and NK cells and at higher levels on blood monocytes, but not on eosinophils nor on blood basophils, respectively, compared with human subjects.
Induction and mechanism of ASA in VG1543 mice
Among human low-affinity hFcgRs, the activating IgG receptors hFcgRIIA and hFcgRIIIA and the inhibitory IgG receptor hFcgRIIB can bind mouse IgG isotypes (Table I) 19, 26, 28, 35, [38] [39] [40] : therefore we explored the capacity of these receptors to mediate ASA triggered by intravenous BSA challenge in VG1505 and VG1543 mice immunized with BSA (see Fig E4 in this article's Online Repository at www. jacionline.org). After challenge, VG1543, but not VG1505, mice experienced a severe decrease in body temperature and 50% to 100% mortality within 30 minutes (Fig 3, A) . Pretreatment of VG1543 mice with blocking antibodies against activating hFcgRIIA (mAb IV.3) 28 abolished hypothermia and mortality (Fig 3, B) . hFcgRIIA is expressed by neutrophils, monocyte/macrophages, eosinophils, basophils, and mast cells in VG1543 mice. Of these, neutrophils, monocyte/macrophages, and basophils have been reported to contribute to IgG-PSA in mice. [17] [18] [19] Neutrophil depletion with either anti-Ly-6G or anti-Gr-1 mAbs protected VG1543 mice from ASA but neither monocyte/macrophage nor basophil depletion affected anaphylaxis induction (Fig 3, C , and see Fig E5, B-E). Finally, PAF-R blockade protected from ASA-associated death and hypothermia, whereas H 1 -receptor antagonist cetirizine had no effect (Fig 3, D , and see Fig E5, F and G) . Altogether, the data obtained in this model of ASA, contingent on hFcgR binding of mouse IgGs, demonstrate that VG1543 mice present with anaphylactic symptoms and a fatal reaction dependent on hFcgRIIA, neutrophils, and PAF. They also demonstrate that mouse FcgRI, which is still expressed in both VG1505 mice and VG1543 mice, cannot induce anaphylaxis.
Aggregated human IVIG triggers PSA in VG1543 mice
Although interactions between mouse IgG isotypes and some human FcgRs can result in induction of anaphylactic reactions (Fig 3 and Table I) , 19, 27, 28 such models are far from recapitulating the variety of human IgG interactions with both activating and inhibitory hFcgRs. 38 Therefore we investigated whether anaphylaxis could be initiated by triggering human FcgRs in VG1543 mice using aggregated human IVIG as a surrogate for human IgG-immune complexes. Intravenous injection of 1 mg of Adapted from data reported in J€ onsson et al, 19 Bruhns et al, 38 Nimmerjahn et al, 39 and Mancardi et al 40 and unpublished data. HA-IVIG induced PSA (IVIG-PSA) in VG1543 mice, which was manifested by visual signs and severe hypothermia, with a maximum temperature loss of 68C to 88C 30 to 40 minutes after injection. This reaction was dependent on hFcgR expression because VG1505 mice were resistant (Fig 4, A) . The dose response to HA-IVIG demonstrated that hypothermia reaches a maximum at 1 mg, was lower at 500 or 300 mg, and was not observed at 30 mg (Fig 4, B , and see Fig E6) . Therefore a dose of 1 mg was chosen for all subsequent episodes of IVIG-PSA because it consistently induced in VG1543 mice a shock at sufficient magnitude to assess the effect of receptor, cell, and mediator blockade. (Fig 3, B) , anti-Ly-6G mAbs or isotype control (Fig 3, C) , and vehicle (NaCl) or PAF-R antagonist ABT-491 (Fig 3, D) . Data are represented as means 6 SEMs and representative of at least 2 independent experiments. Numbers indicate mortality per experimental group; X represents 100% mortality. #P < .05, ##P < .01, and ###P < .001, Log-rank (Mantel-Cox) test for survival. **P < .01, Student t test of individual time points from 10 to 40 minutes.
( Fig 4, C) , even though VG1543 mice express also hFcgRIIIA and hFcgRIIIB, which might induce cell activation. 26, 35, 41 Monocyte/ macrophage depletion caused by toxic liposome administration had no effect (Fig 4, D) , whereas basophil depletion modestly reduced IVIG-PSA in VG1543 mice (Fig 4, E) . However, neutrophil depletion was protective (Fig 4, F) . Appropriate antibody-mediated cell depletion was confirmed by means of flow cytometric analysis (see Fig E1 and Fig E5, A) , and we have previously demonstrated efficient monocyte/macrophage depletion in the blood and spleen after liposome injection. 42 hFcgRIIB blockade, even with high doses of blocking mAbs, did not modulate anaphylactic symptoms in VG1543 mice, whether induced by optimal (1 mg, data not shown) or suboptimal (250 mg; Fig 4, G) doses of HA-IVIG. VG1543 mice are susceptible to PSA induced by human IgG, and the reaction proceeds primarily through neutrophils and the activating receptor hFcgRIIA, with a minor contribution of basophils, but does not require monocytes/macrophages and is not negatively regulated by inhibitory hFcgRIIB.
Changes in hFcgR expression on myeloid cells after anaphylaxis
It has been proposed that changes in Fc receptor expression can be used as a biological marker for anaphylaxis or an indicator of different pathways of activation. 43 Therefore we investigated changes in hFcgR expression on circulating myeloid cell populations after IVIG-PSA in VG1543 mice. One hour after anaphylaxis induction, staining for activating hFcgR receptors was substantially reduced on neutrophils (Fig 5, A) and Ly-6C hi (Fig 5, B) and Ly-6C low (Fig 5, C) monocytes in the blood of VG1543 mice, entailing almost complete loss of hFcgRIIA on neutrophils and monocytes and significant downregulation of hFcgRIII on neutrophils and Ly-6C low monocytes (exemplified in Fig 5, D) . Levels of the inhibitory receptor hFcgRIIB were also significantly reduced on Ly-6C
hi monocytes yet unchanged on Ly-6C low monocytes and neutrophils. These changes in receptor staining were not merely due to increased quantities of circulating IgG because the injection of nonaggregated IVIG did not affect receptor expression (Fig 5, A-D) . Receptor detection by anti-hFcgR mAbs might be influenced by prebound human IgG-immune complexes; however, we confirmed that this was not the case using a panel of different antibodies with different recognition sites, both within and outside the ligand-binding region (see the Methods section and Fig E7 in this article's Online Repository at www.jacionline.org). Furthermore, hIgG could be detected at low amounts on the surfaces of VG1543 neutrophils and monocytes isolated after IVIG-PSA, yet the limited amount of bound hIgG that we observe after PSA, particularly on neutrophils, certainly does not account for the several logs of reduction in receptor staining intensity (Fig E7) . These data indicate active engagement of hFcgR on neutrophils and monocytes during IVIG-PSA and suggest that these cells are each involved in responding to IgG-immune complexes, even though, in the case of monocytes, they might not be required for the induction of anaphylactic symptoms in VG1543 mice.
PAF and histamine contribute to IVIG-PSA in VG1543 mice
We assessed the contribution of the mediators PAF and histamine to IVIG-PSA in VG1543 mice using receptor antagonists administered before PSA induction. PAF-R blockade with 2 (Fig 4, A) or indicated amounts (Fig  4, B) of HA-IVIG, and central temperatures were monitored. C-F, IVIG-PSA (1 mg) in VG1543 mice injected with anti-hFcgRIIA blocking mAbs (Fig 4, C) , toxin-containing liposomes (Fig 4, D) , anti-CD200R3 mAbs (30 mg , Fig 4, E) , anti-Ly-6G mAbs (Fig 4, F) , or corresponding isotype or PBS controls before anaphylaxis induction. G, IVIG-PSA (250 mg) in VG1543 mice injected with indicated amounts of anti-hFcgRIIB blocking mAbs. White or gray squares indicate treated mice; black squares indicate isotype or vehicle controls. In (Fig 5, A) and Ly-6C hi (Fig 5, B) and Ly-6C low (Fig 5, C ) monocytes from VG1543 mice 1 hour after injection of vehicle (NaCl), nonaggregated IVIG (non-agg) or HA-IVIG and PSA induction (HA-IVIG). Background staining on cells from VG1505 mice is shown 1 hour after injection of HA-IVIG. Values represent D geometric mean between specific staining and corresponding isotype or fluorescence-minus-one control pooled from 3 independent experiments. D, Representative histograms. Background staining of isotype control is indicated by shaded histograms, and VG1505 mice are indicated by gray histograms. *P < .05 and ***P < .001, unpaired t test with Welch correction. different antagonists (ABT-491 and CV-6209) significantly reduced the hypothermia associated with IVIG-PSA in VG1543 mice (Fig 6, A and B) . Cetirizine, pyrilamine, and triprolidine are different histamine receptor 1 antagonists that inhibit IgEinduced PSA to various extents (see Fig E8, A-C, in this article's Online Repository at www.jacionline.org). Cetirizine had no effect on IVIG-PSA in VG1543 mice, unless combined with the PAF-R antagonist ABT-491 (see Fig E8, D and E) . However, pyrilamine and triprolidine significantly reduced the hypothermia associated with IVIG-PSA in VG1543 mice (Fig 6, C and D) . Of note, the PAF-R antagonist ABT-491 injected at higher doses did not confer greater protection (see Fig E8, F) . Therefore both PAF and histamine contribute to IVIG-PSA, which is in agreement with the contribution of neutrophils and basophils, in knock-in mice expressing human low-affinity IgG receptors.
DISCUSSION
We demonstrate here that VG1543 mice, which exhibit genuine expression of all human low-affinity FcgRs, are susceptible to IgG-dependent anaphylaxis. VG1543, but not VG1505, mice experienced severe hypothermia after transfer of aggregated human IgG or after immunization and challenge with the same antigen. For the first time, these data show that in a cognate context of activating and inhibitory human FcgR signaling, immune complexes formed by either mouse or human IgG can trigger cell activation, mediator release, and severe anaphylaxis.
Several transgenic mouse models have been developed previously to investigate the in vivo functions of human FcgRs. 14, 35 Transgenic approaches have their inherent flaws, however, in terms of reproducibility of human FcgR expression, heterogeneity of transgene expression between subjects of the same genotype, and instability between generations, as a result of random transgene integration into the genome. 29, 45 Furthermore, the study of hFcgR transgenic strains necessitates genetic backgrounds lacking endogenous mFcgRs because mouse and human FcgRs cross-bind human and mouse IgG, respectively (Table I) . hFcgR-transgenic mice have been studied on a background deficient in the FcRg chain signaling subunit (FcRg KO ), which lacks functional expression of mFcgRI, mFcgRIII, mFcgRIV, and mFcεRI. 47 Unfortunately FcRg KO mice have deficiencies in signaling through several non-FcR molecules, including integrin, cytokine, and growth factor receptors, affecting leukocyte recruitment and vascular hemostasis, and these mice maintain inhibitory mFcgRIIB expression that can modulate hFcgR-induced signaling. 38 and therefore the IgG 2 component of aggregated IVIG might bias toward hFcgRIIA(H 131 ) engagement over the other hFcgRs expressed in VG1543 mice. hFcgRIIA blockade also protected VG1543 mice from systemic anaphylaxis and death after immunization and challenge with the same antigen. This is a less physiologic model because it relies on human hFcgR cross-binding mouse IgGs. Among the activating receptors expressed in VG1543 mice, only hFcgRIIA binds mouse IgG 1 (Table I) , the predominant IgG isotype produced during ASA immunization, and therefore logically predominantly contributes to anaphylaxis induction.
Although the protective effect of hFcgRIIA blockade in the setting of IVIG-PSA suggests that hFcgRIIIA and hFcgRIIIB are not individually capable of triggering systemic anaphylaxis, we cannot formally exclude a cooperative role of these receptors in anaphylaxis induction through hFcgRIIA in VG1543 mice. Indeed, we could not efficiently block hFcgRIIIA, hFcgRIIIB, or both in vivo by using available anti-hFcgRIII antibodies (data not shown). We observed significant hFcgRIIIA/B downregulation on circulating neutrophils and monocytes after IVIG-PSA but not after injection of nonaggregated IVIG (Fig  6) , supporting the notion that these receptors are actively engaging with IgG immune complexes, despite not triggering a systemic reaction. Indeed, in models of autoantibody-induced inflammation, hFcgRIIA and hFcgRIIIB expressed on neutrophils were found to individually and cooperatively promote immune complex-induced reactions; however, hFcgRIIA alone promoted associated injury and inflammation, whereas hFcgRIIIB rather mediated homeostatic clearance of immune complexes, 41, 52 suggesting that hFcgRIIA, but not hFcgRIIIB, is able to induce detrimental reactions in vivo. Anaphylaxis induced by aggregated IVIG was also demonstrated in the hFcgRI tg IIA tg IIB tg IIIA tg IIIB tg mFcgR null mouse model, 29 but the contributing hFcgRs were not identified.
Importantly, VG1505 and VG1543 mice still express the high-affinity mouse receptor mFcgRI, which is expressed on monocytes, tissue-resident monocyte-derived cells, and specific macrophage populations (see Fig E4, F) . 26, 53, 54 Even so, VG1505 mice were resistant to IVIG-PSA (and active anaphylaxis) induction, demonstrating that mFcgRI alone cannot trigger anaphylaxis and that anaphylactic reactions in VG1543 mice rely exclusively on hFcgR triggering. We previously reported that the human counterpart of mFcgRI, hFcgRI (CD64), was sufficient to induce systemic anaphylaxis in transgenic mice lacking 3 FcgRs and 2 FcεRs (but still expressing mouse FcgRIV). 27 For this former study, we used the only reported hFcgRI transgenic mouse: it expresses this receptor on monocytes and macrophages as in human subjects but also constitutively on neutrophils, contrary to human subjects. 35, 55 Anaphylaxis in these mice relied on both neutrophils and monocytes/macrophages. 27 hFcgRI is not expressed in the VG1543 background, and the question remains open whether hFcgRI can participate in IgG-induced anaphylaxis in the context of native hFcgR expression. We have developed a novel hFcgRI knock-in mouse strain that does not present the discrepant expression of existing hFcgRI-transgenic models 29, 55 : hFcgRI is expressed on monocytes, macrophages, and dendritic cells but not constitutively on neutrophils (data not shown). We are currently crossing this mouse strain to VG1543 mice to create a fully hFcgR-humanized knock-in mouse model, which should enable us in the future to address the relative contribution of hFcgRI in a model recapitulating all hFcgR expression.
Anaphylaxis is driven by the release of anaphylactogenic mediators from myeloid cells. 4, 56 Therefore the contribution of any given cell population is determined by the requisite expression of activating FcgR, the capacity of the cells to release active mediators, and a cell's potential for negative inhibition of FcgR signaling by expression of inhibitory FcgRIIB. 57 In wild-type mice, pathways of ASA and passive IgG anaphylaxis rely predominantly on monocyte and/or neutrophil activation through mFcgRIII, with a minor contribution of mFcgRIV and subsequent PAF release. 18, 19, 58 Considering genetic evolution, the functional homolog of mFcgRIII is hFcgRIIA and that of mFcgRIV is hFcgRIIIA (H. Watier, personal communication). 35 Therefore it is consistent that hFcgRIIA, which exhibits prominent expression on all circulating myeloid cells, like mFcgRIII, might be the predominant IgG receptor contributing to anaphylaxis in VG1543 mice. We previously demonstrated that transgenic expression of hFcgRIIA(R 131 ) was sufficient to induce PSA and ASA and that IgG-induced PSA in hFcgRIIA (R 131 ) tg mFcgRI/IIB/ III KO mice required monocytes and neutrophils. 28 Here we identify that neutrophils are mandatory for anaphylaxis in VG1543 mice, whereas we could not identify a contribution for monocytes/macrophages, although they express hFcgRIIA. This discrepancy between mouse models might be due to expression of inhibitory hFcgRIIB, which is absent in hFcgRIIA (R 131 ) tg mFcgRI/IIB/III KO mice but increased on VG1543 blood monocytes compared with that seen in human subjects. Blood monocytes express hFcgRIIB consistently in VG1543 mice, but we and others have identified variable hFcgRIIB on monocytes, particularly CD14 lo blood monocytes, and prominent expression on only a fraction of human donors (see Fig E5, A-E) . 36 However, spleen monocytes significantly express hFcgRIIB in human subjects 36 and VG1543 mice. Indeed, hFcgRIIB binds to all subclasses of human IgG 38 and therefore might inhibit monocyte activation after engagement by IVIG aggregates in VG1543 mice. On the one hand, we observed downregulation of inhibitory hFcgRIIB on circulating Ly-6C hi and Ly-6C low monocytes after IVIG-PSA, suggesting its engagement by IVIG-immune complexes and potential inhibitory signaling by this receptor; on the other hand, hFcgRIIB blockade did not modulate anaphylactic symptoms in VG1543 mice. hFcgRIIB and the inhibitory signals it can induce do not appear to regulate this model of anaphylaxis. These data do not favor a contribution of monocytes to anaphylaxis in VG1543 mice. However, we cannot exclude a potential contribution of blood monocytes (mostly hFcgRIIB negative) to human anaphylaxis.
The contribution of basophils to anaphylaxis models in mice remains controversial: mIgG 1 -induced PSA 17 and mIgG 2a -induced PSA 58 were inhibited after antibody-mediated basophil depletion, but mIgG 1 -induced PSA was unaffected in Mcpt8-cre mice, which exhibit greater than 90% basophil deficiency. 59 In an active model of peanut-induced anaphylaxis involving both IgE and IgG, both antibody-and diphtheria toxin-mediated basophil depletion significantly reduced hypothermia. 60 Human basophils express variable levels of hFcgRIIA and high levels of hFcgRIIB, yet could not be activated by hIgG immune complexes in vitro, suggesting that hFcgRIIB-dependent negative regulation is dominant over hFcgRIIA-dependent basophil activation.
37
VG1543 mice express hFcgRIIA at low levels on circulating basophils but within the range of that observed on peripheral blood cells from healthy donors (Fig 2) . Unlike human basophils, however, VG1543 basophils do not express hFcgRIIB: that we do not identify a major contribution of basophils to anaphylaxis in VG1543 mice cannot be due to hFcgRIIB inhibition of hFcgRIIA-mediated signaling.
We reported previously that neutrophils predominantly contribute to ASA in wild-type mice and that the transfer of human neutrophils can restore anaphylaxis in resistant mice. 13, 19 Neutrophils were mandatory for IVIG-PSA (and ASA) in VG1543 mice because neutrophil depletion abolished hypothermia and protected from death. Both of these anaphylaxis models were dependent on hFcgRIIA, which is expressed at very high levels on both human and VG1543 mouse neutrophils, whereas inhibitory hFcgRIIB expression is found only on a small subset of neutrophils. This low or absent hFcgRIIB expression implies that, unlike monocytes, neutrophil activation is not or marginally regulated by inhibitory hFcgRIIB. Neutrophils also contributed to hFcgRIIA-dependent PSA in hFcgRIIA(R 131 ) tg mFcgRI/IIB/ III KO mice 28 in the absence of other hFcgR expression. We demonstrate now that the contribution of neutrophils to IgGinduced anaphylaxis is also predominant in the context of native hFcgR expression in VG1543 mice. Such an observation is of crucial consideration when we acknowledge that neutrophils comprise more than 60% of circulating blood cells in human subjects. Finally, we identified that the soluble mediator PAF was responsible for a significant proportion of IVIG-PSA-induced hypothermia (and ASA-associated death), a finding concurrent with a dominant pathway initiated by hFcgRIIA on neutrophils. Neutrophils are indeed the major producers of PAF in human subjects. 61 Among the 3 histamine receptor antagonists tested, 2 (pyrilamine and tripolidine) significantly inhibited IVIG-induced anaphylaxis by themselves, and 1 (cetirizine) only had an effect when combined with PAF-R antagonists. These findings suggest that both PAF and histamine contribute to hypothermia and mortality in the VG1543 model. These results are in agreement with the inefficacy of H 1 -antihistamine treatment alone on systemic anaphylactic symptoms in patients. Reports by Vadas and colleagues indicate a correlation between levels of circulating PAF, rather than histamine, with anaphylaxis severity 12 and identified PAF as a central mediator of human anaphylaxis pathogenesis, 62 which aligns with our findings reported herein using locusswapped human low-affinity hFcgR KI mice. Our data indicate that IgG-dependent anaphylaxis in VG1543 mice proceeds through an activating pathway dependent on hFcgRIIA and neutrophils, with a contribution of basophils and driven by the mediators PAF and histamine. Although expressed in this novel knock-in mouse model, hFcgRIIIA and hFcgRIIIB were not sufficient to trigger anaphylaxis. That such drastic anaphylaxis induction is possible in the context of native inhibitory and activating hFcgR expression suggests a similar pathway can occur in human subjects. VG1543 mice represent an attractive knock-in model for the study of human low-affinity IgG receptors, in which the encoding genes remain expressed in their cognate genetic environment, including intergenic sequences, and consequently, cell-surface expression largely reflects that of human subjects. Although the polymorphisms expressed in the VG1543 mouse represent a section of subjects within the population, other subjects express alternate and/or heterozygous polymorphisms, some of which have been demonstrated to predispose to immunologic susceptibility or resistance.
14 It would be clinically relevant to extend studies in hFcgR knock-in mice to understand the effect of hFcgR polymorphisms on cell activation and subsequent biological responses and therefore on sensitivity to anaphylaxis or other allergic diseases involving IgG antibodies.
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Clinical implications: In a mouse model of cognate human IgG receptors expression, hFcgR engagement with IgG immune complexes induced severe anaphylaxis. These findings benefit the understanding of human IgG-dependent anaphylaxis, whether nonclassical (IgE independent) or after IgG-based therapies.
METHODS
Generation of mFcgRIIB, mFcgRIII, and mFcgRIV knockout mice
A targeting construct (Fig 1, A) for deleting mouse Fcgr2b, Fcgr3, and FcgR4 genes (encoding mFcgRIIB, mFcgRIII, and mFcgRIV, respectively) in a single targeting step was constructed by using VelociGene technology.
E1
Mouse sequences were obtained from BAC clone RP23-395F6. A donor fragment was constructed by cloning a neomycin cassette flanked by one lox66 and one lox71 site specific recombination site (lox'd). More specifically, the 59 mouse homology arm, corresponding to 270 bp of mouse sequence located 3796 bp downstream of Fcgr2b, underwent PCR with oligos (see Tables E1  and E2 ) and cloned upstream of a mutant lox'd neomycin selection cassette followed by a mouse 39 homology arm corresponding to 342 bp of mouse sequence (PCR with the oligos noted in Tables E1 and E2 ) located 4001 bp upstream of the ATG of Fcgr3. This donor fragment was inserted into Escherichia coli strain DH10B containing the mouse BAC clone RP23-395F6 and a recombination enzyme vector. Cells were grown in drug selection medium.
Upon bacterial homologous recombination (BHR) at the locus, a drug selection cassette replaces the Fcgr2b, Fcgr3, and Fcgr4 genes. Individual clones were grown, and the targeted BAC DNA that contains a lox'd drug cassette in place of the Fcgr2b, Fcgr3, and Fcgr4 genes was extracted. Targeted cells were identified by means of PCR with the up detect primer set and down detect primer set (see Tables E1 and E2 ). Part of the vector was sequenced to confirm proper mouse-cassette junctions, and pulsed field gel electrophoresis was used to establish insert size and expected restriction fragment length.
The targeting vector (LTVEC) VG1505 was linearized and used to electroporate VGF1 mouse ES cells. Upon BHR at the locus 106 kb of the endogenous Fcgr2b, the Fcgr3 and Fcgr4 locus is thereby deleted and replaced by a lox'd neomycin cassette, resulting in an ES cell that does not express endogenous Fcgr2b, Fcgr3, and Fcgr4 genes. Correctly targeted ES cells were introduced into an 8-cell stage mouse embryo by using the VelociMouse method. E2 VelociMice (F0 mice fully derived from the donor ES cell) bearing the deleted Fcgr2b, Fcgr3, and Fcgr4 genes were identified by means of genotyping for loss-of-mouse allele by using a modification-of-allele assay (see Table E3 ).
Generation of knock-in hFcgRIIA(H 131 )-hFcgRIIB(I 232 )-hFcgRIIC(Stop 13 )-hFcgRIIIA(V 158 )-hFcgRIIIB(NA2) mice Targeting constructs (Fig 2, B and C) for subsequent humanization of mouse mFcgRs by using 2 sequential targeting steps were constructed with VelociGene technology. E1 For the first targeting construct, VG1528, human sequences were obtained from BAC clone CTD-2514J12. BACvec VG1528 was constructed in 4 steps, as described in Tables E1 and E2 . In step 1 a donor fragment was constructed by cloning a hygromycin cassette flanked by site specific frt recombination sites (frt'd). More specifically, the 59 BAC backbone homology arm, corresponding to 384 bp of pBeloBAC11, underwent PCR by using oligos (see Table E1 ) and cloned upstream of a frt'd hygromycin selection cassette followed by a human 39 homology arm corresponding to 342bp of human sequence (undergoing PCR with oligos in Tables E1 and E2 ) located 19 kb upstream of the human FCGR3A gene (encoding hFcgRIIIA). BHR with this donor fragment deleted 41 kb from the 59 end of CTD-2514J12, replacing it with an I-CeuI site and the frt'd hygromycin cassette to make VI209.
In step 2 VI209 was modified by using BHR to insert a PI-SceI site and spec cassette at the 39 end to make VI212 (see Tables E1 and E2 ).
In step 3 RP23-395F6 was modified by using BHR to delete the entire 106-kb mouse low-affinity mFcgR locus (Fcgr2b, Fcgr3, and Fcgr4 genes), replacing it with a lox'd neomycin cassette flanked by a 59 I-CeuI site and a 39 PI-SceI site. The extra PI-SceI site in the backbone was then deleted by means of AscI digestion and ligation to make VI208.
In step 4 the 69-kb human hFcgR-encoding fragment from VI212 was ligated into the I-CeuI and PI-SceI sites of VI208, replacing the lox'd neomycin cassette to make the final LTVEC VG1528.
For the second targeting construct, VG1543, human sequences were obtained from BAC clone RP11-697E5. BACvec VG1543 was constructed in 3 steps, as described in Tables E1 and E2 . In step 1 a donor fragment was constructed by cloning a spectinomycin cassette flanked by site-specific recombination sites. More specifically, the 59 homology arm, corresponding to 59 bp of human sequence and BAC backbone sequence that is 4558 bp downstream of FCGR3A, was ligated to a spectinomycin selection cassette followed by a 39 homology arm corresponding to 333 bp of the backbone sequence in pBACe3.6. BHR with this donor fragment trimmed the human hFcgR locus on the proximal end of RP11-697E5, deleting the PI-SceI site to make VI217.
In step 2 VI217 was modified by using BHR with a donor fragment consisting of 59 homology arm corresponding to 258 bp of BAC backbone sequence in pBACe3.6, a frt'd hygromycin cassette flanked by a 59 NotI site and a 39 PI-SceI site, and a 39 homology arm corresponding to 274 bp of human sequence 1188 bp upstream of FCGR2B to make VI222.
In step 3 the 47-kb mouse distal homology arm with lox'd neomycin cassette from VI208 was ligated into the NotI and PI-SceI sites of VI222, replacing the frt'd hygromycin cassette to make the final LTVEC VG1543.
The targeting vectors were linearized and used to electroporate mouse ES cells. E3 Upon BHR at the locus, 106 kb of the endogenous mouse low-affinity FcgR locus (Fcgr2b, Fcgr3, and Fcgr4 genes) is thereby deleted and replaced by human FCGR2B, FCGR3B, FCGR2C, FCGR3A, and FCGR2A genes (encoding hFcgRIIB variant I 232 , hFcgRIIIB variant NA2, hFcgRIIC variant stop 13 , hFcgRIIIA variant V 158 , and hFcgRIIA variant H 131 ) by sequential targeting of VG1528 and VG1543, resulting in an ES cell that expresses lowaffinity human hFcgR genes instead of endogenous low-affinity mouse mFcgR genes. Correctly targeted ES cells were introduced into an 8-cell stage mouse embryo by using the VelociMouse method. E2 VelociMice (F0 mice fully derived from the donor ES cell) bearing the human FCGR2B, FCGR3B, FCGR2C, FCGR3A, and FCGR2A genes were identified by means of genotyping for loss-of-mouse allele and gain-of-human allele by using a modification-of-allele assay (see Table E3 ).
Antibodies and reagents
perfused with cold PBS before dissection and processed with the Gentle-MACS liver dissociation kit and the Octo Dissociator (Miltenyi Biotec). Cells were isolated from the peritoneum by means of lavage with 6 mL of cold PBS; BAL was performed 3 times with 1 mL of PBS. For blood leukocyte analysis, a precise volume of heparinized blood was subjected to RBC lysis and washed with MACS buffer.
Flow cytometry
Human EDTA-collected blood was obtained from the blood bank Etablissement Français du Sang. After red blood cell lysis, leukocytes were stained with fluorescently labeled mAbs for 30 minutes at 48C. Human cell populations were distinguished as CD15 ). hFcgRIIA was identified by the specific mAb clone IV.3. hFcgRIIB was identified by the clone 2B6 E5 expressed as a chimeric mouse-human IgG 1 N 297 A variant to inhibit unspecific binding through the Fc portion of the antibody. We used an anti-CD16 antibody (clone 3G8) to characterize jointly hFcgRIIIA and hFcgRIIIB expression because we could not identify, by using a series of commercially available anti-CD16 antibodies, an antibody able to distinguish surface expression of hFcgRIIIA(V 158 ) from hFcgRIIIB(NA2). In Fig E7 the anti-CD32 clone FLI8.26 defines hFcgRIIA1B expression, the anti-CD32(R131) clone 3D3 defines hFcgRIIB expression only because VG1543 mice express the H131 variant of hFcgRIIA, and the anti-CD16 clone MEM-154 defines hFcgRIIIA1B expression. mFcgRI was identified by using the specific clone X54-5/7.1 (BD Biosciences).
For ex vivo binding of cells with human IgG, blood cell suspensions were incubated first with aggregated IVIG (20 mg/mL) for 1 hour on ice and then stained with a fluorescently labeled antibody cocktail, including anti-human IgG Fab-specific goat F(ab') 2 fragment (Jackson ImmunoResearch, West Grove, Pa). Cells isolated from VG1543 mice after IVIG-PSA were stained with the secondary antibody alone.
Samples were run on a MACSQuant flow cytometer (Miltenyi Biotec), and data were analyzed with FlowJo Software (TreeStar, Ashland, Ore).
Specificity and efficiency of cell depletion strategies
Appropriate antibody-mediated cell depletion with anti-Ly-6G (NIMP-R14) and anti-CD200R3 (Ba103) was examined by means of flow cytometric analysis. NIMP-R14 treatment (300 mg) efficiently depleted neutrophils in the blood, spleen, and peritoneum (Fig E1) . Percentages of total CD11b 1 CD115
1 monocytes in the blood and CD11b 1 Gr-1 int monocytes in the spleen were unaffected, whereas percentages of CD11b 1 F4/80 1 macrophages in the peritoneum increased slightly. The percentage of blood basophils was slightly increased, but total numbers were unaffected, and spleen basophils and peritoneal mast cells were not affected. However, we observed that the frequency of Ly-6C hi monocytes decreased and the frequency of Ly-6C low monocytes increased after NIMP-R14 treatment, a phenomenon that might reflect epitope masking by NIMP-R14 because of low-level cross-recognition. Therefore NIMP-R14 efficiently depletes neutrophils, with some effects on other cell populations. Ba103 administration at 30 mg per mouse induced basophil depletion in the blood and spleen without affecting circulating neutrophils and monocytes or peritoneal mast cells (Fig E3 and data not shown ). Yet basophil depletion was incomplete (up to 70%) and not uniformly efficient across subjects (see Fig E3, A) . Therefore we administered Ba103 at a 2-fold greater dose (60 mg per mouse). Although we could not detect a significant increase in depletion compared to the 30 mg dose (data not shown), this increased dose indicated a minor contribution of basophils to anaphylaxis severity (Fig 4, E) .
We have previously demonstrated efficient monocyte/macrophage depletion in the blood and spleen after intravenous liposome injection, E6 whereas peritoneal macrophages remained intact. In an effort to achieve complete monocyte/macrophage depletion, we combined multiple injections of clodronate liposomes with different routes of administration, resulting in higher total liposome load: however, these approaches were inconclusive, and although we were efficiently able to deplete resident macrophages, we observed increases in numbers of circulating inflammatory monocytes and wildly inconsistent responses during IVIG-PSA. Indeed, toxic liposomes can affect all phagocytic cell populations, and approaches to increase their efficacy also augment nonspecific effects. For this study, we confirmed that the ability of macrophages to mediate thrombocytopenia (reflecting capacity to engage and engulf antibody-bound cells and, by logical extension, immune complexes) remains intact after antibody-mediated depletion strategies (eg, NIMP-R14 or Ba103) but is blocked after intravenous clodronate liposome injection at the doses used herein.
Statistics
Statistical analyses were performed with Prism software (GraphPad Software, La Jolla, Calif). Survival was analyzed by using a log-rank (Mantel-Cox) test to compare test subjects and control subjects. Temperature loss during ASA was compared with a Student t test of individual time points, excepting Fig E5, G, in which groups were compared using a 2-way repeated measures ANOVA. Temperature loss during PSA was compared by using 2-way repeated-measures ANOVA, except in Fig E8, E , in which groups were compared by using a Student t test at 30 minutes. hFcgR expression in Fig  5 and Fig E7 was compared by using an unpaired t test with the Welch correction for unequal variances. Percentages of immune cell populations in Table  E4 were compared using an unpaired t test.
FIG E1.
Antibody clone NIMP-R14 specifically targets Ly-6G antigen and efficiently depletes neutrophils in vivo. A-C, Blood sampled from naive mice (pool of n 5 4) was stained with fluorescein isothiocyanateconjugated NIMP-R14 in combination with fluorescent antibody clones 1A8 (anti-Ly-6G; Fig E1, A) , RB6-8C5 (anti-Gr-1, binds Ly-6C and Ly-6G; Fig E1, B) , or anti-Ly-6C (Monts 1; Fig E1, C) with or without preblocking with an excess of unconjugated NIMP-R14 or 1A8. Staining was assessed by using flow cytometry, and representative plots are shown pregated on single live CD11b 1 cells. D-F, VG1543 mice were treated with 300 mg of NIMP-R14 or rat isotype control antibody (rIgG 2b ), blood and tissues were sampled 24 hours later, and frequencies of specific cell populations were determined by using flow cytometry: gating strategies are shown, as are frequencies of neutrophils and monocyte/macrophages in the blood (Fig E1, D) , spleen ( Fig  E1, E) , and peritoneum (Fig E1, F) . G-I, Percentage of basophils in the blood (Fig E1, G) and spleen (Fig E1, H) and mast cells in the peritoneum (Fig E1, I) . Fig E1, D-F , Data are pooled from 2 independent experiments.
FIG E2.
VG1505 and VG1543 mice demonstrate normal immune cell composition of major compartments and comparable expression of mFcεRI and mFcgRI. A, Spleens taken from VG1505 and VG1543 mice were comparable in size. B and C, Leukocyte counts in total blood were enumerated by using an automatic blood cell analyzer (Fig E2, B) , and frequencies of blood immune cell populations (Fig E2, C; see also (Fig E3, C) . Numbers indicate D geometric mean between specific staining and fluorescence-minus-one controls. Data are representative of at least 2 independent experiments (n > 3). Fig E3, D and E, Discrimination of classical versus patrolling monocyte subsets in the blood of VG1543 mice (Fig E3, D) or human donors (Fig E3, E) . Differential hFcgRIIA, hFcgRIIB, and hFcgRIII expression on monocyte subsets is shown by representative histograms. Shaded gray histograms indicate background staining from VG1505 mice; shaded blue histograms indicate background staining with an isotype control antibody (hFcgRIIA and hFcgRIII) or a fluorescence-minus-one control (hFcgRIIB). Fig E3, 
FIG E5.
Basophils, monocyte/macrophages, and histamine were not found to contribute to BSA-ASA in VG1543 mice. A, VG1543 mice were treated with 30 mg of anti-CD200R3 (Ba103) or rat isotype control antibody (rIgG 2b ), and blood and tissues were sampled 24 hours later: representative gating strategy and percentage of basophils in the blood and spleen and percentage of mast cells in the peritoneum. B-G, Change in body temperature and survival during BSA-ASA in VG1505 and VG1543 mice and VG1543 mice treated with anti-Gr-1 mAbs (Fig E5, B) , toxic liposomes ( Fig E5, C and E) , anti-CD200R3 mAbs (Fig E5, D) , the H 1 -receptor antagonist cetirizine (Fig E5, F) , the PAF-R antagonist ABT-491 (Fig E5, G) , or respective controls. Data are represented as means 6 SEMs and are representative of at least 2 independent experiments. Fig E5, E, BSA-ASA with high mortality in VG1543 mice treated with PBS or toxin-containing liposomes before challenge (repeat of Fig E5, C) . Fig E5, G, BSA-ASA with no mortality in VG1543 mice treated or not with PAF-R antagonist before challenge (repeat of Fig 3, D) . *P < .05, Student t-test of individual time points from 10 min; ***P < .001 2-way repeated measures ANOVA. Fcgr2b  AGCAGTGCTGCCTCCTTCC  TGACCATCGTGGAAGCCAGCCT  GGTTTGTTTCCCTTTGCCAGTATG  0  1  Neo  Neo gene  GGTGGAGAGGCTATTCGGC  TGGGCACAACAGACAATCGGCTG  GAACACGGCGGCATCAG  0  1  1528 hT1  Fcgr2b  TCATCACGACTTACCTGGGTTC  CCCTCCTGGTGTCCCTCTGATGAC  GGACAGGTGAAGACAGAGGAG  1  0  1528 hT1  Fcgr2b  TCCTTCCTGGTCCTGTTCTATG  TCCCTTGCCAGACTTCAGACTGAGA  CTCTGTCACCCACCAATTTCC  0  0  Hyg  Hyg  TGCGGCCGATCTTAGCC  ACGAGCGGGTTCGGCCCATTC  TTGACCGATTCCTTGCGG  0  0  1543hD  Fcgr2b  GTTCTGGTAATTGGGCTCTTTGTTC  TCTGGAGCTTCCGACTGCATAAGCAG  ACTGCTGGTTTCTGCCTTCTC  0  0  1543hU  Fcgr2b  GGGAGAATAGCAGAGCAGGAC  TCAGCAATCTCCACTCAGGGCTCA  ACACAAGTTCACGGGAAGTCAAAC  0  0  1543 AS 129  Fcgr2b  TTTCTTGCCCCAAATTGAAGA  CTCCCAAATGAATG  TCAGGCAGTCGATCTCTGTTTC  0  0  1543 AS B6  Fcgr2b  TTTCTTGCCCCAAATTGAAGA  CTCCCAAATGAGTGGAG  TCAGGCAGTCGATCTCTGTTTC  1  0  1543 AS2 129  Fcgr4  TTCTTGTGTCTCCTTTGCCTCTAA  ATCCACTTAGACTGCAC  TTGAAGCTCTGCACAGTGAGATC  1  0  1543 AS2 B6  Fcgr4  TTCTTGTGTCTCCTTTGCCTCTAA  TATCCACCTAGACTGC  TTGAAGCTCTGCACAGTGAGATC  1  0  1543 AS3 129  Fcgr4  GGCAGGACAGTGATAAATTCTGAGA  TGGCCCTTGCTGTGA  GGCCAAGAATGGAACATGACTT  1  0  1543 AS3 B6  Fcgr4  GGCAGGACAGTGATAAATTCTGAGA  TGGCCCTTGCTATGA  GGCCAAGAATGGAACATGACTT  1  0  1  0 Mod, Modified allele; WT, wild-type. 
